Group 1: Service Consumption Policies - The Ministry of Commerce and nine other departments released measures to expand service consumption, proposing 19 initiatives across five areas, including the launch of "Service Consumption Season" activities [3] - The initiatives aim to enhance the supply of quality services to meet diverse consumer demands, reflecting new consumption trends such as rational quality consumption and emotional value consumption [3] Group 2: Meta's AI Glasses - Meta announced the Meta Connect 2025 event scheduled for September 17-18, where CEO Mark Zuckerberg will share updates on AI glasses and the company's vision for AI and the metaverse [4] - Two new smart glasses are expected to be unveiled, one featuring a display and priced around $800, targeting a more premium market compared to existing products priced at $300 [4][5] Group 3: Robotics Industry Growth - The humanoid robot industry is anticipated to see significant growth, with Tesla starting factory audits and suppliers receiving notifications for new orders [6] - Research indicates that Tesla's Gen3 model is expected to produce 30,000 to 50,000 units, with plans for a Gen4 model, while domestic companies like Yushu Technology are accelerating their IPO processes [6] Group 4: Investment Trends - Foreign investment institutions have been actively researching high-end manufacturing and technology innovation companies, with nearly 400 foreign institutions conducting around 1,800 research sessions since July [11] - The focus of these institutions includes sectors such as industrial machinery, electrical equipment, electronic instruments, and healthcare [11]

（文章来源：证券日报） 证券日报网讯 9月16日晚间，新华制药发布公告称，近日，公司之全资子公司山东淄博新达制药有限公 司收到国家药品监督管理局核准签发的熊去氧胆酸胶囊《药品注册证书》。 ...

格隆汇9月16日丨新华制药(000756.SZ)公布，近日，山东新华制药股份有限公司之全资子公司山东淄博 新达制药有限公司(以下简称"新达制药")收到国家药品监督管理局核准签发的熊去氧胆酸胶囊《药品注 册证书》。 本品用于治疗胆囊胆固醇结石(必须是X射线能穿透的结石，同时胆囊收缩功能须正常);胆汁淤积性肝病 (如：原发性胆汁性肝硬化);胆汁反流性胃炎。新达制药申报的熊去氧胆酸胶囊于2025年9月获得批准， 有利于丰富公司消化系统用药品种，提升公司综合竞争力。 ...

新华制药9月16日晚间公告，公司全资子公司山东淄博新达制药有限公司获得国家药品监督管理局核准 签发的熊去氧胆酸胶囊《药品注册证书》。该药品为化学药品4类，规格250mg，用于治疗胆囊胆固醇 结石（必须是X射线能穿透的结石，同时胆囊收缩功能须正常）；胆汁淤积性肝病（如：原发性胆汁性 肝硬化）；胆汁反流性胃炎。 ...

Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration of two new drugs, indicating a positive development in its product pipeline and potential revenue growth [1] Group 1: Drug Approvals - The company has obtained a drug registration certificate for Sildenafil Citrate Orally Disintegrating Tablets, which are used to treat erectile dysfunction [1] - The company's wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has also received approval for Ursodeoxycholic Acid Capsules, indicated for the treatment of cholesterol gallstones, cholestatic liver disease, and bile reflux gastritis [1]

新华制药（000756）(000756.SZ)公告，公司全资子公司山东淄博新达制药有限公司(简称"新达制药")收 到国家药品监督管理局核准签发的熊去氧胆酸胶囊《药品注册证书》。该药品用于治疗胆囊胆固醇结石 (必须是X射线能穿透的结石，同时胆囊收缩功能须正常);胆汁淤积性肝病(如：原发性胆汁性肝硬化);胆 汁反流性胃炎。 ...

Group 1 - The core point of the article is that Xinhua Pharmaceutical (000756.SZ) announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., received the drug registration certificate for Ursodeoxycholic Acid Capsules from the National Medical Products Administration [1] - The drug is indicated for the treatment of cholesterol gallstones (which must be X-ray penetrable stones and the gallbladder must have normal contraction function) [1] - It is also used for cholestatic liver diseases (such as primary biliary cirrhosis) and bile reflux gastritis [1]

截至发稿，新华制药市值为116亿元。 每经头条（nbdtoutiao）——海拔4306米现"秦始皇密令"，获官方"身份认定"！古文字学家刘钊：秦人 寻仙采药足迹确至青藏高原 （记者 王晓波） 每经AI快讯，新华制药（SZ 000756，收盘价：16.81元）9月16日晚间发布公告称，近日，山东新华制 药股份有限公司之全资子公司山东淄博新达制药有限公司收到国家药品监督管理局核准签发的熊去氧胆 酸胶囊《药品注册证书》。 2025年1至6月份，新华制药的营业收入构成为：化学药品制剂制造业占比44.36%，化学药品原药制造 业占比32.11%，医药中间体及其他占比23.53%。 ...

Core Viewpoint - Xinhua Pharmaceutical's subsidiary, Xinda Pharmaceutical, has received the drug registration certificate for Ursodeoxycholic Acid Capsules from the National Medical Products Administration, indicating a significant development in its product portfolio [1] Company Summary - Xinda Pharmaceutical, a wholly-owned subsidiary of Xinhua Pharmaceutical, has been approved for Ursodeoxycholic Acid Capsules, which are used to treat cholesterol gallstones, cholestatic liver disease, and bile reflux gastritis [1] - The drug is classified as a Class A item in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog for 2024, enhancing its market accessibility [1] Industry Summary - The estimated sales revenue for Ursodeoxycholic Acid in Chinese public medical institutions is approximately 2.155 billion yuan in 2024, indicating a substantial market opportunity for the newly approved drug [1] - Xinda Pharmaceutical submitted the application for marketing authorization in January 2024 and received approval in September 2025, reflecting the regulatory timeline for new drug approvals in the industry [1]

Group 1 - The company announced that its wholly-owned subsidiary, Shandong Zibo Xinda Pharmaceutical Co., Ltd., has received the drug registration certificate for Ursodeoxycholic Acid Capsules from the National Medical Products Administration [1] - The drug is indicated for the treatment of cholesterol gallstones, cholestatic liver disease, and bile reflux gastritis [1] - The estimated sales revenue for Ursodeoxycholic Acid in Chinese public medical institutions is approximately RMB 2.155 billion in 2024 [1]